



URGENT

Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION			
LAST NAME:	FIRST NAME:		
PHONE NUMBER:	DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:			
CITY:	STATE:	ZIP CODE:	
PATIENT INSURANCE ID NUMBER:	·		

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: __

FOLLOWING LINK: HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): ______ AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: ______

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION				
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):				

Continued on next page.







Tykerb (lapatinib) Prior Authorization Request Form





MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
🗆 Breast cancer				
Other diagnosis:ICD-:				
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Clinical Information:				
Does the patient have a diagnosis of advanced or metastatic breast cancer? \square Yes \square No				
Select if the patient has HER2 positive disease confirmed by the following laboratory test results:* Immunohistochemistry (IHC) assay 3 or more Fluorescence in situ hybridization (FISH) Assay greater than 2.2 				
Will Tykerb be used as first-line therapy in combination with letrozole? \square Yes \square No				
Will Tykerb be used in a post-menopau	usal woman for whom hormonal therap	y is indicated? Yes No		
Will Tykerb be used in combination wi	th capecitabine? \square Yes \square No			
Has the patient received prior therapy with all three types of chemotherapy: an anthracycline, taxane, and trastuzumab?* \square Yes \square No				
Aside from lymph node involvement, is the patient's metastatic disease confined to the brain? 🗆 Yes 🗆 No				
Has the patient already received whole-brain radiotherapy and/or stereotactic radiosurgery? Yes D No *Please provide documentation.				
Reauthorization:				
If this is a reauthorization request, answer the following question: Select if the patient's tumor responded with stabilization of disease or decrease in size of tumor or tumor spread, as confirmed by the following measures:* Complete hematologic remission at 3 months Complete, partial, or minor cytogenetic response at 6 months Complete or partial cytogenetic response at 12 months Complete cytogenetic response at 18 months *Please provide documentation.				







Tykerb (lapatinib) **Prior Authorization Request Form Caterpillar Prescription Drug Benefit**



Phone: 877-228-7909 Fax: 800-424-7640

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811

St. Paul, MN 55164-0811



